MedPath

Combining Wearable Technology to Crate Internet+Digital Hospital-remote Home Type 2 Diabetes Follow-up Management Mode

Not Applicable
Completed
Conditions
Diabetes Mellitus, Type 2
Interventions
Device: Remote monitoring devices+Internet management platform
Registration Number
NCT04973644
Lead Sponsor
Second Affiliated Hospital of Nanchang University
Brief Summary

This study intends to combining wearable technology to crate Internet+Digital Hospital-remote Home Type 2 Diabetes follow-up management mode.To preliminarily explore compared with the traditional medical treatment mode, whether the new management mode of DM can improve the management objectives and patient satisfaction of T2DM and reduce medical costs. The study provides a powerful reference for establishing corresponding platforms and promoting such models at the government management level in the future.

Detailed Description

Background:The prevalence of T2DM in Chinese adults has exceeded 10%, and the prevalence of abnormal glucose metabolism has exceeded 40% in people older than 18 years. This will lead to a significant increase in the prevalence of DM complications in the next decade, and the disability and death caused by complications will also seriously affect the quality of life of patients and bring a huge social and economic burden.This randomized controlled trial intends to combining wearable technology to crate Internet+Digital Hospital-remote Home T2DM follow-up management mode.To preliminarily explore compared with the traditional medical treatment mode, whether the new management mode of DM can improve the management objectives and patient satisfaction of T2DM and reduce medical costs. The study provides a powerful reference for establishing corresponding platforms and promoting such models at the government management level in the future.

Methods:The study was a parallel-group, randomised, controlled trial. the number of cases planned to be included in 200 cases. Participants were randomly assigned to the intervention or control group.The intervention group receives Internet + Digital Hospital-remote home management mode,including remote monitoring devices+Internet management platform, dietary recommendations, exercise supervision, web education, information pushing, doctor-patient interaction, etc.The control group receives the traditional management mode, including routine dietary and exercise recommendations, education as well as monitor in the clinic.

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
120
Inclusion Criteria
  • Diagnosed with type 2 diabetes according to the World Health Organization criteria;
  • Aged between 18 and 70 years;
  • Glycosylated haemoglobin (HbA1C%) between 7% and 9%.
Exclusion Criteria
  • Type 1 diabetes;
  • Gestational diabetes;
  • Other special types of diabetes;
  • Moderate-severe insufficiency of heart , liver, kidney and lung;
  • Complicated with acute disease or stress status.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Arm && Interventions
GroupInterventionDescription
Internet + Digital Hospital-remote home management modeRemote monitoring devices+Internet management platformRemote monitoring devices+Internet management platform, dietary recommendations, exercise supervision, web education, information pushing, doctor-patient interaction.
Primary Outcome Measures
NameTimeMethod
HbA1c concentrationBaseline, Week 12, Week 24

HbA1c concentration reflects the average blood glucose level

Secondary Outcome Measures
NameTimeMethod
Waist circumferenceBaseline, Week 24

Waist circumference is an important index to determine central obesity.

BMIBaseline, Week 24

BMI is an internationally used measure of how fat and thin a person is and whether they are healthy or not.The calculation formula is: BMI= weight/height\^2.

Serum uric acidBaseline, Week 24

Serum uric acid is the end product of purine catabolism.Is excreted by the kidney with urine.Serum uric acid measurement is a sensitive marker for the diagnosis of severe renal impairment.

FBGBaseline, Week 24

Normal FBG values are 3.9 to 6.1 mmol/L

Fasting insulinBaseline, Week 24

Insufficient insulin secretion or insulin resistance is a major cause of diabetes

Blood pressureBaseline, Week 24

Normal systolic blood pressure \<140mm Hg, diastolic blood pressure\<90mmHg in China.

Total cholesterolBaseline, Week 24

Total cholesterol refers to the sum of cholesterol contained by all lipoproteins in the blood.Normal Total cholesterol values \<5.17 mmol/L

TriglyceridesBaseline, Week 24

Normal Triglycerides values Triglycerides\<1.7 mmol/L

LDL-CBaseline, Week 24

The level of LDL-C is correlated with the incidence and severity of cardiovascular disease

HDL-CBaseline, Week 24

The level of HDL-C is inversely associated with coronary heart disease.

WeightBaseline, Week 24

Standard weight is one of the important signs to reflect and measure a person's health status

Serum creatinineBaseline, Week 24

Clinically detecting serum creatinine is one of the main methods to understand renal function, and it is an important indicator of kidney function, and an elevated serum creatinine means the damage of kidney function.

Urinary microalbumin / creatinine ratioBaseline, Week 24

Urinary microalbumin /creatinine ratio is the test used clinically to judge microalbuminuria, examine early renal lesions, and is more commonly used clinically for early diabetic nephropathy.

Diabetes Treatment Satisfaction QuestionnaireWeek 24

Comments on the distribution of treatment satisfaction scores measured by the Diabetes Treatment Satisfaction Questionnaire (DTSQ).There are 8 items in total, including three dimensions of treatment satisfaction, self-perceived hyperglycemia and self-perceived hypoglycemia.The minimum and maximum values are 0 and 36 ,respectively.Higher scores mean a better outcome.

Trial Locations

Locations (1)

The Second Affiliated Hospital Of Nanchang University

🇨🇳

Nanchang, Jiangxi, China

© Copyright 2025. All Rights Reserved by MedPath